PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy

BACKGROUND: The rapid development of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors has generated an urgent need for biomarkers assisting the selection of patients eligible for therapy. The use of PD-L1 immunohistochemistry, which has been suggested as a predictive biomarker,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Gevensleben, Heidrun, Holmes, Emily Eva, Goltz, Diane, Dietrich, Jörn, Sailer, Verena, Ellinger, Jörg, Dietrich, Dimo, Kristiansen, Glen
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346762/
https://ncbi.nlm.nih.gov/pubmed/27835597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13161
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items